NEU 0.15% $13.13 neuren pharmaceuticals limited

ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-159

  1. 6,199 Posts.
    lightbulb Created with Sketch. 1648
    IMO, this represents a 'potential' glaring error in the wording of the contract, because if push came to shove, Acadia would very likely succeed in any litigation, simply due to a literal reading of the contract wording.

    I say 'potential', because (once again IMO) it is quite unlikely that the two companies would engage in a dog fight, when there is a high probability that any TO of Neuren would involve a simultaneous or subsequent TO of Acadia, by the acquiring company, giving it total ownership of the original Neuren technology.

    So perhaps the loose contract wording may have been overlooked due to recognition of the likelihood of the above scenario playing out.

    [Lots of holes there I guess, but at least it puts MY mind at rest.]
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.